PMID: 8602999Feb 1, 1996Paper

Feasibility of peripheral blood progenitor cell harvest and transplantation in patients with poor-risk myelodysplastic syndromes

British Journal of Haematology
H DemuynckM Boogaerts

Abstract

Myelodysplastic syndromes (MDS) are a group of clonal haematological disorders with a highly unfavourable prognosis. Allogeneic bone marrow transplantation offers the sole possibility for cure and prolonged survival, but is only available for a minority of patients. Therefore, we investigated the feasibility of PBPC collection and transplantation in 11 patients with high-risk myelodysplasia who were not eligible for allogeneic bone marrow transplantation. In six patients, PBPC were harvested after mobilization with G-CSF alone. Five patients were harvested during the recovery phase of intensive chemotherapy combined with G-CSF. This resulted in seven patients in an adequate CD34 progenitor yield > 1 x 10(6)/kg. Six patients obtained a CFU-GM content of the PBPC harvest > 10 x 10(4)/kg. Five patients were subsequently transplanted following a standard BuCy4 regimen. The median to ANC (absolute neutrophil count) > or = 0.5 and 1.0 x 10(9)/l was respectively 14 d (range 10-18) and 16 d (range 11-25). Platelets were self-supporting > or = 20 x 10(9)/l after a median of 41 d (ranges 8-144). One patient had a persistent lack of platelet engraftment unresponsive to infusion of back-up bone marrow. These data demonstrate that in select...Continue Reading

Citations

Oct 21, 2004·Best Practice & Research. Clinical Haematology·John McCarty
Dec 12, 2001·Critical Reviews in Oncology/hematology·F D Pisani, A Rainaldi
Apr 29, 2000·Current Opinion in Hematology·G SeipeltD Hoelzer
Sep 19, 2003·Wiener klinische Wochenschrift·Peter ValentKlaus Geissler
May 7, 1998·Leukemia & Lymphoma·A Ganser, M Karthaus
Jun 25, 1998·Leukemia & Lymphoma·K Sawada
Oct 27, 2007·Seminars in Hematology·Theo de WitteNicolaus Kröger
Mar 1, 1996·Baillière's Clinical Haematology·M A BoogaertsH Demuynck
Jul 29, 2000·Blood Reviews·J E Anderson
Jun 13, 2002·Reviews in Clinical and Experimental Hematology·Theo de WitteAnton Schattenberg
Aug 31, 2002·Bone Marrow Transplantation·S Luger, N Sacks
Nov 25, 2004·Hematology·Alan F ListTheo M DeWitte
Nov 25, 2003·Hematology·Ghulam MuftiAloysius Y L Ho

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.